Durvalumab showed significant improvements in event-free survival and overall survival in muscle-invasive bladder cancer patients compared to chemotherapy alone. The phase 3 NIAGARA study involved ...

TAR-200 monotherapy achieved an 83.5% complete response rate in BCG-unresponsive high-risk NMIBC patients, with a high insertion success rate of 98.8%. The treatment was well tolerated, with most ...

TARA-002 showed a 70% high-grade complete response rate in NMIBC patients, with 72% at six months. The treatment was effective in both BCG-unresponsive and BCG-naïve patients, with CR rates of 80% and ...

The trial targets intermediate-risk non-muscle invasive bladder cancer, focusing on superficial stage A, primarily low-grade tumors. Cretostimogene grenadenorepvec is compared to surveillance in a ...

The study analyzed mCRPC patients with HRRm treated with olaparib, focusing on real-world treatment outcomes and biomarker testing patterns. Patients were stratified by treatment line and prior ...

Early and aggressive treatment strategies are crucial for improving outcomes in high-risk metastatic castration-sensitive prostate cancer. Combining androgen deprivation therapy with novel hormonal ...

Belzutifan's safety profile was evaluated in 576 patients with advanced RCC across four clinical trials, revealing a high incidence of adverse events. Anemia was the most common adverse event, ...

Intravesical chemotherapy aims to reduce recurrence and progression but may have limited efficacy and potential side effects. PD-L1 inhibitors enhance immune response but can cause immune-related ...

PT217 targets DLL3 and CD47, receiving FDA fast track and orphan drug designations for neuroendocrine prostate cancer and carcinoma. The SKYBRIDGE trial evaluates PT217's safety, tolerability, and ...

Panelists discuss how the management of metastatic castration-sensitive prostate cancer involves a multidisciplinary approach, utilizing androgen deprivation therapy, chemotherapy, and novel agents to ...

Decision-making in NMIBC is increasingly complex due to a better understanding of disease nuances and heterogeneity. Balancing treatment burden, toxicity, and bladder preservation versus radical ...

Cretostimogene grenadenorepvec demonstrated a 74.5% overall complete response rate in high-risk BCG-unresponsive NMIBC patients. At 12 months, 97.3% of patients were free from progression to ...